rizatriptan has been researched along with Vestibular Diseases in 1 studies
rizatriptan: structure given in first source; RN given refers to benzoate
Vestibular Diseases: Pathological processes of the VESTIBULAR LABYRINTH which contains part of the balancing apparatus. Patients with vestibular diseases show instability and are at risk of frequent falls.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A previous pilot study suggested that rizatriptan reduces motion sickness induced by complex vestibular stimulation." | 9.15 | Rizatriptan reduces vestibular-induced motion sickness in migraineurs. ( Balaban, CD; Furman, JM; Marcus, DA, 2011) |
| "A previous pilot study suggested that rizatriptan reduces motion sickness induced by complex vestibular stimulation." | 5.15 | Rizatriptan reduces vestibular-induced motion sickness in migraineurs. ( Balaban, CD; Furman, JM; Marcus, DA, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Furman, JM | 1 |
| Marcus, DA | 1 |
| Balaban, CD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Rizatriptan on Rotational Motion Sickness in Migraineurs[NCT00360282] | 36 participants (Actual) | Interventional | 2006-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Scores are based on a scale developed by Graybiel which rates seven subjective and objective signs of motion sickness. The total scores ranged from from 0 to 25. Zero indicating no motion sickness. Greater than 16 indicates severe motion sickness. Trials were stopped if scores were 16 or greater. Scores were taken before and after each rotation. (NCT00360282)
Timeframe: Pre and Post Stimulus (about 6 minutes apart)
| Intervention | units on a scale (Median) |
|---|---|
| Rizatriptan Visit | 5.1 |
| Placebo Visit | 9 |
Subjective report of distress ranging from 0 to 10 based on the method of Wolpe. Zero indicates no distress and 10 indicates severe distress. Measures used in this analysis match the times used in the analysis for Outcome 1. (NCT00360282)
Timeframe: Pre and Post Stimulus (6 minutes apart)
| Intervention | units on a scale (Median) |
|---|---|
| Rizatriptan Visit | 3 |
| Placebo Visit | 2 |
1 trial available for rizatriptan and Vestibular Diseases
| Article | Year |
|---|---|
Rizatriptan reduces vestibular-induced motion sickness in migraineurs.
Topics: Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Motion Sickness; | 2011 |